Gene expression signature with independent prognostic significance in epithelial ovarian cancer Journal Article
| Authors: | Spentzos, D.; Levine, D. A.; Ramoni, M. F.; Joseph, M.; Gu, X.; Boyd, J.; Libermann, T. A.; Cannistra, S. A. |
| Article Title: | Gene expression signature with independent prognostic significance in epithelial ovarian cancer |
| Abstract: | Purpose: Currently available clinical and molecular prognostic factors provide an imperfect assessment of prognosis for patients with epithelial ovarian cancer (EOC). In this study, we investigated whether tumor transcription profiling could be used as a prognostic tool in this disease. Methods: Tumor tissue from 68 patients was profiled with oligonucleotide microarrays. Samples were randomly split into training and validation sets. A three-step training procedure was used to discover a statistically significant Kaplan-Meier split in the training set. The resultant prognostic signature was then tested on an independent validation set for confirmation. Results: In the training set, a 115-gene signature referred to as the Ovarian Cancer Prognostic Profile (OCPP) was identified. When applied to the validation set, the OCPP distinguished between patients with unfavorable and favorable overall survival (median, 30 months v not yet reached, respectively; log-rank P = .004). The signature maintained independent prognostic value in multivariate analysis, controlling for other known prognostic factors such as age, stage, grade, and debulking status. The hazard ratio for death in the unfavorable OCPP group was 4.8 (P = .021 by Cox proportional hazards analysis). Conclusion: The OCPP is an independent prognostic determinant of outcome in EOC. The use of gene profiling may ultimately permit identification of EOC patients appropriate for investigational treatment approaches, based on a low likelihood of achieving prolonged survival with standard first-line platinum-based therapy. © 2004 by American Society of Clinical Oncology. |
| Keywords: | immunohistochemistry; survival; adult; cancer survival; human tissue; treatment outcome; aged; middle aged; survival analysis; major clinical study; genetics; mortality; multimodality cancer therapy; chemotherapy, adjuvant; combined modality therapy; cancer staging; methodology; neoplasm staging; sensitivity and specificity; neoplasm; ovarian neoplasms; metabolism; genetic predisposition to disease; ovary cancer; gene expression; ovariectomy; tumor markers, biological; pathology; tumor marker; risk assessment; rna; gene expression regulation; gene expression regulation, neoplastic; biopsy, needle; adjuvant chemotherapy; ovary tumor; needle biopsy; prediction and forecasting; predictive value of tests; dna fingerprinting; genetic predisposition; rna, neoplasm; complementary dna; dna, complementary; neoplasms, glandular and epithelial; humans; prognosis; human; female; priority journal; article |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 22 |
| Issue: | 23 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2004-12-01 |
| Start Page: | 4700 |
| End Page: | 4710 |
| Language: | English |
| DOI: | 10.1200/jco.2004.04.070 |
| PROVIDER: | scopus |
| PUBMED: | 15505275 |
| DOI/URL: | |
| Notes: | J. Clin. Oncol. -- Cited By (since 1996):140 -- Export Date: 16 June 2014 -- CODEN: JCOND -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work